Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.32  

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

 
 

NON-EXCLUSIVE LICENSE and SUPPLY AGREEMENT
  between
  IMMUNICON CORPORATION
  and
  MOLECULAR PROBES, INC.    
    

        THIS NON-EXCLUSIVE LICENSE and SUPPLY AGREEMENT (hereinafter "Agreement"), dated and effective as of the Effective Date (as hereinafter defined), by
and between Immunicon Corporation, a corporation organized and existing under the laws of the Commonwealth of Pennsylvania, having an office at 3401 Masons Mill, Suite 100, Huntingdon Valley,
Pennsylvania 19006, and its Affiliates (hereinafter collectively, "Immunicon"), and Molecular Probes, Inc., a corporation organized and existing under the laws of Oregon, having an office at
4849 Pitchford Avenue, Eugene, Oregon 97402, and its Affiliates (hereinafter collectively, "MProbes"), on behalf of each of them and their Affiliates (as the term is hereinafter defined). 

WITNESSETH:

        WHEREAS,
Immunicon possesses skills in manufacturing and labeling magnetic particles for various uses and MProbes possesses skills in manufacturing and marketing detection technology for
various uses; and 

        WHEREAS,
each party wishes to cooperate in the development, manufacturing, marketing and sales of products incorporating such magnetic particles for life science applications in the
magnetic separation and fluorescent detection markets; and 

        WHEREAS,
MProbes wishes to receive from Immunicon, and Immunicon wishes to supply MProbes, under the terms and conditions of this Agreement, various Magnetic Separation Materials (as
hereinafter defined), for incorporation by MProbes into Licensed MP Products (as hereinafter defined) intended to be sold solely for life science applications that do not require formal governmental
regulatory approval prior to sale; and 

        WHEREAS,
in order to accomplish the foregoing, Immunicon is willing to grant to MProbes, under the terms and conditions of this Agreement, certain limited rights under Immunicon's
proprietary technology relating to magnetic particle separation, with respect to such life science applications of Licensed MP Products; 

        NOW,
THEREFORE, in consideration of the foregoing premises, the mutual covenants herein contained and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows: 

        1.    DEFINITIONS.    

        Certain
terms are used in this Agreement as specifically defined herein. In addition: 

        1.1   "Affiliate"
when used with respect to either Party, means any corporation, association, partnership, joint venture, trust, organization, or other business entity or
subdivision thereof that directly or indirectly controls, is controlled by or is under direct or indirect common control with such Party. 

        1.2   "Effective
Date" means November 1, 2000. 

1

 

        1.3   "IC
Hardware" means IC Magnets and other products, other than reagents, that are supplied by Immunicon to MProbes hereunder for use in conjunction with the Magnetic
Separation Materials; IC Hardware supplied under this Agreement is listed in Appendix A. 

        1.4   "IC
Magnets" means proprietary magnets that are supplied by Immunicon to MProbes hereunder for use in conjunction with Magnetic Separation Materials. 

        1.5   "IC
Technology" means Immunicon's patents and patent applications ("IC Patents") and other proprietary information and know-how relating to cell analysis
technology and Magnetic Separation Materials, which is directly relevant to the production, promotion, marketing and sale of Licensed MP Products, and which is provided to MProbes by Immunicon
pursuant to this Agreement. IC Patents relevant to this Agreement are listed in Appendix D. 

        1.6   "IC
Trademark" means any trademarks authorized by Immunicon to be used by MProbes in connection with Licensed MP Products during the term of this Agreement; IC
Trademarks authorized for use under this Agreement are listed in Appendix A. 

        1.7   "Licensed
MP Products" means the authorized products listed in Appendix C and packaged, marketed and sold by MProbes hereunder that incorporate Magnetic
Separation Materials. 

        1.8   "Licensed
Use" means use of Licensed MP Products in any life science application only by the end-user, provided that such life science application is not a
Regulated Use. For purposes of this Agreement, "Regulated Use" means any use that occurs in a clinical or diagnostic laboratory environment, and the use or the results thereof are subject to
regulation or control by any governmental body or regulating authority. Licensed Use expressly excludes, by way of example but not limitation, any human and veterinary in vivo or in vitro diagnostic
application such as screening, diagnosis, staging or monitoring of disease; any in vivo imaging; any therapeutic use; and any use approved by, or for which approval could or must be sought, from the
US Food and Drug Administration or from any comparable agency in any country other than the US. 

        1.9   "Magnetic
Separation Materials" means the specific magnetic reagents listed in Appendix A (e.g. [**]) that will be supplied by Immunicon
for use by MProbes according to the terms of this Agreement. 

        1.10 "Net
Sales" means the actual price (including quantity or distributor discounts) at which the transfer of the Licensed MP Product to the customer is made, net of any
separately invoiced shipping charges, taxes, or government fees on the transfer of such Licensed MP Product; and net of any royalties up to [**] of the sale price of the
Licensed MP Product and payable to third parties that is necessary for the manufacture, use, or sale of the Licensed MP Product, provided that, for the purposes of defining net sales, payments to
third parties for the supply of products or their components are not considered royalties. 

        1.11 "Territory"
means all countries of the world. 

        2.    TERM AND TERMINATION.    

        2.1   This
Agreement shall commence on the Effective Date, and continue for the life of the relevant IC Patents, unless one of the termination options identified in this
Article 2 applies. 

        2.2    Termination by Mutual Consent.    This Agreement shall terminate upon the mutual written agreement of the
parties. 

**  Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

2

 

        2.3    Termination by Immunicon with Termination Fee.    This Agreement shall terminate upon notice by Immunicon of
the intended termination date, delivered in accordance with Article 13 thereof, where such notice is given at least twelve months after the Effective Date of the license, and at least twelve
months prior to such intended termination date, and Immunicon pays MProbes a $150,000 termination fee. 

        2.4    Termination by MProbes.    This Agreement shall terminate upon notice by MProbes of the intended termination
date, delivered in accordance with Article 16 hereof, where such notice is given at least ninety days prior to such intended termination date. 

        2.5    Termination for Financial Difficulties.    Either party shall have the right to terminate this Agreement upon
thirty (30) days notice to the other party, if such other party becomes involved in financial difficulties as evidenced: 

        a)    by
such other party's commencement of a voluntary case under any applicable bankruptcy code or statute, or by its authorizing, by appropriate proceedings, the
commencement of such a voluntary case; or 

        b)    by
such other party's failing to receive dismissal of any involuntary case under any applicable bankruptcy code or statute within sixty (60) days after initiation
of such action or petition; or 

        c)     by
such other party's seeking relief as a debtor under any applicable law of any jurisdiction relating to the liquidation or reorganization of debtors or to the
modification or alteration of the rights of creditors, or by consenting to or acquiescing in such relief; or 

        d)    by
the entry of an order by a court of competent jurisdiction finding such other party to be bankrupt or insolvent, or ordering or approving its liquidation,
reorganization, or any modification or alteration of the rights of its creditors or assuming custody of, or appointing a receiver or other custodian for all or a substantial part of its property or
assets; or 

        e)    by
such other party making an assignment for the benefit of, or entering into a composition with, its creditors, or appointing or consenting to the appointment of a
receiver or other custodian for all or a substantial part of its property. 

        2.6    Termination for Material Breach.    If either party breaches or defaults in the performance or observance of
any of the material provisions of this Agreement, and such breach or default is not cured within sixty (60) days after the giving of notice by the other party specifying such breach or default,
the non-defaulting party shall have the right to terminate this Agreement, effective with ten (10) days further notice to the defaulting party. The failure by a party to exercise
its right to terminate this Agreement pursuant to this Section 2.6 in the event of any occurrence giving rise thereto shall not constitute waiver of its rights in the event of any subsequent
occurrence. 

        2.7   Following
the expiration of the relevant IC Patents, Immunicon grants MProbes a right of first negotiation to continue the sale and distribution of IC Magnets and
conjugates of IC BSA Ferrofluids and kits containing such conjugates, for life science applications other than for Regulated Use. 

        2.8   Immunicon
also grants MProbes a right of first negotiation on IC Technology for life science applications other than for Regulated Use, in the event that Immunicon
decides to focus its efforts exclusively in the area of Regulated Use and discontinue its efforts in all other applications. 

3

 

        2.9   Except
as otherwise provided in this Agreement, upon any expiration or termination of this Agreement: 

        a)    All
rights, privileges and licenses granted hereunder shall immediately terminate and revert to Immunicon, and MProbes shall not thereafter make any use whatsoever of any
Magnetic Separation Materials, IC Technology or IC Trademarks, and shall not further market, sell, or distribute any Licensed MP Products; 

        b)    MProbes
shall promptly return or provide to Immunicon, upon the request of Immunicon, all IC Technology and other confidential information disclosed by Immunicon and
existing in tangible form regarding Licensed MP Products, except that MProbes may keep an archival copy of such confidential information of Immunicon in the legal department of MProbes to verify its
obligations under this Agreement; 

        c)     MProbes
shall promptly destroy or transfer to Immunicon, at Immunicon's election, all marketing, labeling, or advertising materials relating to Licensed MP Products or IC
Trademarks; and 

        d)    MProbes
shall pay to Immunicon, within thirty (30) days following such expiration or termination, all amounts due to Immunicon pursuant to the terms and conditions
of this Agreement. 

        2.10 The
provisions of Articles 1, 10, 11, 14, 15 and Section 2.9 hereof shall survive any expiration or termination of this Agreement, together with any other
express right, obligation or duty of the parties which by its nature would survive. 

        3.    RIGHTS GRANTED MPROBES WITH RESPECT TO MAGNETIC SEPARATION MATERIALS.    

        3.1   MProbes
shall, while this Agreement is in effect, have the non-exclusive limited right and license, without the right to sublicense: 

        a)    to
incorporate, or have incorporated, Magnetic Separation Materials supplied by Immunicon hereunder into Licensed MP Products; 

        b)    to
sell or have sold Licensed MP Products or IC Hardware, solely for the Licensed Use in the Territory, either directly to end-users or through MProbes'
standard distribution
channels, where the Licensed MP Products or IC Hardware are sold as packaged by MProbes (with MProbes' standard packaging) and are not repackaged, derivatized, or incorporated into another product by
a third party before transfer to the ultimate consumer; and 

        c)     to
use or have used the IC Trademarks and IC Technology in the Territory solely in connection with the marketing, selling and distributing of Licensed MP Products and/or
IC Hardware, and solely for the Licensed Use in the Territory. 

        3.2   No
other rights or licenses are granted hereunder, it being expressly understood and agreed, by way of example but not limitation, that no right or license is granted to
MProbes hereunder to research, develop, reproduce, copy or reverse engineer Magnetic Separation Materials, to make or have made any Magnetic Separation Materials, to otherwise use or sell Magnetic
Separation Materials or Licensed MP Products or IC Hardware except as permitted herein, or to directly or indirectly develop, produce, market, promote, encourage use of, exploit, offer for sale, sell
or have sold, distribute or have distributed, or otherwise dispose of, Licensed MP Products or IC Hardware in the Territory for any use other than the Licensed Use. 

        3.3   While
this Agreement is in effect, Immunicon shall, by way of example and not by way of limitation, have and retain the rights to develop, make, have made, market, sell,
distribute and use any Magnetic Separation Materials or Licensed MP Products; and to conduct any research and 

4

 

development
or testing activity with respect to Magnetic Separation Materials or Licensed MP Products. Immunicon shall, in addition, retain the right to sell Magnetic Separation Materials to any third
party that approaches Immunicon with respect to purchasing Magnetic Separation Materials before approaching MProbes and independently of marketing efforts of MProbes, regardless of the end use of such
Magnetic Separation Materials by such third party, including without limitation the use thereof in or in connection with Licensed MP Products within the scope of the Licensed Use. 

        3.4   The
rights retained by Immunicon pursuant to paragraph 3.3 notwithstanding, however, nothing in this Agreement grants Immunicon any rights to develop, make, have
made, sell, distribute, or use any proprietary materials or methods or other intellectual property right of MProbes, whether or not protected by patent, trademark or copyright, unless agreed in
writing beforehand between the parties. 

        3.5   If,
during the term of this Agreement, Immunicon desires to grant rights to MProbes with respect to new Licensed MP Products to be marketed and sold by MProbes within
the scope of the Licensed Use as herein defined, the parties shall consider a separate written definitive agreement, or an appropriate amendment to this Agreement, as determined by MProbes and
Immunicon through good faith negotiations. 

        4.    MARKETING OF LICENSED MP PRODUCTS.    

        4.1   MProbes
shall in good faith make reasonable commercial efforts and make reasonable expenditures to diligently market and promote sales of Licensed MP Products for the
Licensed Use in the Territory. MProbes' good faith efforts and expenditures will be at least comparable to MProbes' efforts and expenditures for other MProbes' products. 

        4.2   MProbes
shall provide Immunicon with information about any proposed Licensed MP Products to be marketed and promoted for sale by MProbes as a catalog item, at least
sixty (60) days prior to the first commercialization of such proposed Licensed MP Products. 

        4.3   MProbes
shall cause to have placed on all Licensed MP Products or IC Hardware produced, marketed or sold hereunder, or on the accompanying product literature, a suitable
and clearly legible legend that clearly restricts such Licensed MP Products and IC Hardware to the Licensed Use, such legend to be in content and language(s) appropriate to the particular country or
countries where such Licensed MP Products and IC Hardware are produced, marketed and/or sold and in conformance with all applicable governmental regulatory requirements. Such legend should include, by
way of example but not limitation, the phrase "This product is licensed solely for use in life science applications that are not clinical diagnostic or therapeutic applications" or substantially
equivalent language, indicating appropriate restrictions on use of Licensed MP Products and IC Hardware in accordance with the rights granted MProbes hereunder, and in accordance with US Food and Drug
Administration labeling requirements for products that are not approved for use in diagnostic applications. 

        4.4   MProbes
shall provide a copy of the initial versions of labels and product literature for Licensed MP Products and IC Hardware to Immunicon for review and approval as to
compliance with the requirements of paragraphs 4.3 and 6.2, at least ten (10) days prior to distribution, sale or release of the associated Licensed MP Product or IC Hardware to the market. 

        4.5   MProbes
hereby recognizes and acknowledges that because of the legal and regulatory requirements concerning certain uses of Magnetic Separation Materials, IC Technology
and Licensed MP Products, there exists the legitimate interest of Immunicon in assuring that the foregoing are not used in inappropriate and impermissible ways. Accordingly, in addition to the
marketing requirements of paragraph 4.3 above, MProbes shall use reasonable commercial efforts to monitor its customers and end users of Licensed MP Products sold hereunder to assure 

5

 

compliance
with the Licensed Use hereunder, and shall promptly inform Immunicon in writing of any use by any such customer or end user of which it becomes aware which is not in accordance with the
Licensed Use. 

        4.6   MProbes
shall maintain a bibliography of scientific research publications relating to technical advances in and useful modifications of Licensed MP Products and Licensed
Uses thereof that shall come to its knowledge. Immunicon shall from time to time furnish MProbes with IC Technology as and to the extent Immunicon reasonably determines is necessary to assist MProbes
in such efforts. Management reviews shall be held quarterly, or at intervals mutually agreed between the parties, to review goals, status of marketing and sales activities with respect to Licensed MP
Products, customers and new developments for the Licensed MP Products. 

        5.    PURCHASE OF MAGNETIC SEPARATION MATERIALS AND IC HARDWARE.    

        5.1   During
the term of the Agreement, and subject to all the terms and conditions hereof, Immunicon shall sell Magnetic Separation Materials to MProbes for use and/or
incorporation in Licensed MP Products in the Territory in such quantities as Immunicon is capable of supplying and MProbes may require, expressly subject to the pricing provisions of Article 7
hereof, and MProbes shall purchase such Magnetic Separation Materials exclusively from Immunicon. While this Agreement is in effect and except as provided in Article 11. MProbes shall not,
without Immunicon's prior written consent, sell any other magnetic particle separation product or substance substantially capable of being used, or incorporated into Licensed MP Products, in a similar
manner to Magnetic Separation Materials. For the purposes of this paragraph 5.1, in a "similar manner" means use or incorporation into a product for which Magnetic Separation Materials are
technically and commercially suitable, but does not cover use or incorporation into a product for which Magnetic Separation Materials are not technically or commercially suitable, and for which
MProbes may therefore sell any other magnetic particle separation product or substance without the prior written consent of Immunicon. 

        5.2   The
Magnetic Separation Materials and IC Hardware to be supplied and sold by Immunicon and purchased by MProbes hereunder shall conform to the specifications for same as
set forth in Appendix A, which may be amended from time to time by the parties in writing. 

        5.3   Upon
receipt by Immunicon of a purchase order or equivalent document for Magnetic Separation Materials or IC Hardware from MProbes, Immunicon shall use reasonable
commercial efforts to meet the schedule for delivery requested by MProbes in such document. For each item listed in Appendix A, there is established a commercially reasonable and economical
delivery schedule, and Immunicon shall have no obligation to manufacture or supply Magnetic Separation Materials or IC Hardware to MProbes in advance of such delivery schedule. Immunicon shall notify
MProbes just prior to the shipment of an order. 

        5.4   Except
as otherwise mutually agreed, Immunicon shall ship Magnetic Separation Materials and IC Hardware to MProbes FCA common carrier (INCOTERMS 2000) from the facility
in which such items are manufactured or obtained by Immunicon, and title to and risk of loss of such items shall pass to MProbes upon their delivery to a common carrier. 

        6    MAINTENANCE OF QUALITY/TRADEMARKS.    

        6.1    Quality Standards.    Immunicon shall be responsible for maintaining commercially acceptable quality control
standards in all manufacturing relating to the Magnetic Separation Materials and IC Hardware that it supplies to MProbes hereunder. 

        6.2    Use of IC Trademarks.    The IC Trademarks shall be solely owned by Immunicon. MProbes agrees to use the IC
Trademarks solely in connection with the Licensed MP Products as indicated in Appendix A and in accordance with trademark standards set by Immunicon, and to 

6

 

avoid
taking any action that would in any manner impair or detract from the value of the IC Trademarks or the goodwill and reputation of Immunicon. MProbes hereby acknowledges Immunicon's sole
ownership of the IC Trademarks and related goodwill. MProbes agrees to provide a copy of the use of such IC Trademarks to Immunicon for review, pursuant to paragraph 4.4 above. 

        7.    CONSIDERATION/PRICING.    

        7.1   MProbes
shall compensate Immunicon for the supply of Magnetic Separation Materials and IC Hardware according to the pricing schedule in Appendix B. 

        7.2   In
additional consideration of the rights granted to MProbes hereunder, MProbes shall pay to Immunicon certain percentages of the Net Sales received by MProbes from
sales of Licensed MP Products, on a product-by-product basis while this Agreement is in effect, and other applicable fees, according to the schedule set forth in
Appendix C attached hereto. 

        7.3   Such
payments of percentages of Net Sales due Immunicon hereunder shall be accounted for and paid to Immunicon within thirty (30) days following the close of the
accounting period for each quarter during the term of this Agreement. 

        8.    FORECASTS: ORDERS AND DELIVERIES.    

        8.1   MProbes
shall deliver to Immunicon, within one year after the Effective Date, MProbes' forecast for its requirements of Magnetic Separation Materials for Licensed MP
Products for the remainder of 2001. Thereafter, at least sixty (60) days prior to the start of the next and each succeeding calendar
quarter during the term of the Agreement, MProbes shall provide Immunicon with its non-binding best estimate of its requirements for Magnetic Separation Materials and IC Hardware for the
next succeeding three (3) calendar quarters. Immunicon shall not ship the forecasted items to MProbes, however, until MProbes places an order. 

        8.2   It
is the intent of the parties that MProbes and Immunicon shall cooperate with each other with respect to changes in their requirements and capacity so that each party
may use reasonable commercial efforts to efficiently accommodate the needs of the other. Accordingly, in addition to the forecasts of quarterly requirements required by Section 8.1, MProbes
shall discuss with Immunicon any dramatic changes in its requirements, and Immunicon shall use reasonable commercial efforts, consistent with its then current capacity, to accommodate such dramatic
changes within the next two (2) calendar quarters. In no event shall this Agreement be deemed to be breached or subject to termination if MProbes' requirements hereunder should be reduced to
zero from time to time, or if Immunicon shall fail to supply all of MProbes' requirements of Magnetic Separation Materials from time to time. 

        9.    ACCESS TO BOOKS AND RECORDS.    

        9.1   From
time to time during the term of this Agreement, but not more frequently than two (2) times per year, MProbes shall upon reasonable notice from Immunicon
afford reasonable access to its offices to independent public accountants of Immunicon or other appropriate agents of Immunicon and permit such accountants or agents to inspect MProbes' information,
books and records, subject to appropriate assurances of confidentiality, to verify manufacturing and sales of Licensed MP Products, Net Sales, and the accuracy and completeness of the financial and
other information related to the fulfillment by MProbes of its obligations hereunder. 

7

   
        10.    REPRESENTATIONS, WARRANTIES AND COVENANTS.    

        10.1   Immunicon's Representations, Warranties, and Covenants Immunicon hereby represents, warrants, and
covenants the following: 

        a)    Immunicon
is a corporation duly organized, existing and in good standing under the laws of the Commonwealth of Pennsylvania, with full right, power and authority to enter
into and perform this Agreement and to grant all of the rights, powers, and authorities herein granted. 

        b)    The
execution, delivery and performance of this Agreement do not conflict with, violate, or breach any agreement to which Immunicon is a party, or Immunicon's articles of
incorporation or bylaws. 

        c)     This
Agreement has been duly executed and delivered by Immunicon and is a legal, valid and binding obligation enforceable against Immunicon in accordance with its terms. 

        d)    Immunicon
shall comply with all applicable laws, consent decrees, and regulations of any federal, state, or other governmental authority. 

        e)    To
the best of Immunicon's knowledge and belief as of the Effective Date of this Agreement, there are no issued or pending patent or trademark applications of a third
party that would prevent MProbes from using or selling Licensed MP Products in the Territory for the Licensed Use. 

        10.2   Immunicon
hereby covenants that it shall neither sue nor otherwise attempt to enforce against MProbes any patents or other proprietary rights which
Immunicon now holds, or which Immunicon may acquire or develop hereafter to restrict MProbes from using Magnetic Separation Materials supplied by Immunicon for the making, having made, selling, using
or importing of Licensed MP Products for the Licensed Use under the terms of this Agreement for so long as such Magnetic Separation Materials and Licensed MP Products shall remain subject to the terms
of this Agreement. 

        10.3   Immunicon
shall warrant the IC Hardware sold by MProbes to the same extent that it warrants the same items when such items are sold by Immunicon. 

        10.4    MProbes' Representations. Warranties. and Covenants    MProbes hereby represents, warrants, and covenants the
following: 

        a)    MProbes
is a corporation duly organized, existing and in good standing under the laws of Oregon, with full right, power, and authority to enter into and perform this
Agreement and to grant all of the rights, powers, and authorities herein granted. 

        b)    The
execution, delivery, and performance of this Agreement do not conflict with, violate, or breach any agreement to which MProbes is a party, or MProbes' articles of
incorporation or bylaws. 

        c)     This
Agreement has been duly executed and delivered by MProbes and is a legal, valid, and binding obligation enforceable against MProbes in accordance with its terms. 

        d)    MProbes
shall comply with all applicable laws, consent decrees, and regulations of any federal, state, or other governmental authority. 

        10.5   MProbes
has had the full opportunity to have this Agreement reviewed and approved by its own legal counsel and other advisors, is entering into this
Agreement having made its own independent assessment and judgment concerning the business opportunity and legal rights and obligations under this Agreement and the terms and conditions hereof, and has
not been induced to enter into this Agreement in any way or by any promise not expressly set forth herein. 

8

 

        10.6   Immunicon
shall indemnify, defend, and hold harmless MProbes from any and all damages, cost, expenses, suits, claims and judgments (including reasonable
attorney's fees and costs) arising from the conduct of Immunicon or its officers or employees or arising from the production or sales of Magnetic Separation Materials or IC Hardware by Immunicon to
MProbes, except for any claims, liability, damages, loss of expense caused by MProbes' breach of the warranties herein. 

        10.7   MProbes
shall indemnify, defend, and hold harmless Immunicon from any and all damages, cost, expenses, suits, claims and judgments (including reasonable
attorney's fees and costs) arising from the
conduct of MProbes or its officers or employees or arising from the production, use or sales of Licensed MP Products by MProbes, except for any claims, liability, damages, loss, cost, or expense
caused by Immunicon's breach of the warranties herein. 

        10.8    Indemnification Procedure.    In the event of any claim under this Article 10, the party claiming the
right to indemnity (the "Claimant") shall promptly notify the indemnifying party (the "Indemnitor") of such claim. Thereafter: 

        a)    The
Indemnitor will undertake the defense thereof by representatives of Indemnitor's own choosing reasonably satisfactory to Claimant. Claimant may, at its sole option
and expense, elect to participate in such defense, but the Indemnitor shall assume the direction and control of such defense. The Claimant shall, at its expense, assist in and cooperate with the
Indemnitor and its agents and insurers in the defense of such claims. 

        b)    If
Indemnitor, within a reasonable time after notice of any such claim, fails to defend, Claimant will (upon further notice to the Indemnitor) have the right to undertake
the defense, compromise or settlement of such claim for the account of Indemnitor, subject to the fight of Indemnitor to assume the defense of such claim with counsel reasonably satisfactory to
Claimant at any time prior to settlement, compromise or final determination thereof. 

        c)     Anything
in this Article 10 to the contrary notwithstanding. Indemnitor shall not, without Claimant's prior written consent, settle or compromise any claim or
consent to entry of any judgment with respect to any claim for anything other than money damages paid by Indemnitor which would have any adverse effect on Claimant, Indemnitor may, without Claimant's
prior written consent, settle or compromise any claim or consent to entry of any judgment with respect to any claim which requires solely money damages paid by Indemnitor and which includes as an
unconditional term thereof the release of Claimant by the plaintiff from all liability in respect of such claim. 

        10.9    Rejection and Return.    If any of the Magnetic Separation Materials or IC Hardware supplied by Immunicon
hereunder breaches any warranty herein, MProbes shall promptly notify Immunicon of such breach and may reject such Magnetic Separation Materials or IC Hardware within ninety (90) days after
such breach should have reasonably been discovered and return such Magnetic Separation Materials or IC Hardware, if applicable, to Immunicon at Immunicon's expense. 

        11.    FORCE MAJEURE.    

        11.1   Neither
party hereto shall be considered in default in the performance of its obligations hereunder to the extent that the performance thereof is
prevented or delayed by strikes, labor difficulties, war (declared or undeclared), act of God or the public enemy, rebellions, civil strife, riots, interference by civil or military authorities,
compliance with governmental laws, or rules and regulations or any other cause which is beyond the control of such party; provided, however, that the party whose performance is prevented from due
performance hereunder by the force majeure shall use its reasonable efforts to remove the disability and recommence due performance hereunder at the earliest reasonable time. 

9

 

        11.2   On
the happening of an event of force majeure, the party forced by the event of force majeure to suspend performance (the "Suspending Party") shall
promptly advise the other party (the "Recipient Party") of the event of force majeure, the cause thereof and, to the extent reasonably possible its best estimate of the duration of the suspension (the
"Failure Period"). The notice described in this paragraph shall hereinafter be referred to as the "Suspension Notice." 

        11.3   If
a failure of performance due to a force majeure occurs and continues for a period in excess of fourteen (14) days, or if a Suspension Notice
advises the Recipient Party that a failure of performance will continue for a period in excess of fourteen (14) days, then the Recipient Party may, at its option, contract with any person for
an alternate supply of any item or service to which the failure of performance applies. Any such contract shall be referred to hereafter as an "Alternate Source Contract." 

        11.4   The
Recipient Party shall use all good faith, consistent with sound business practice, to obtain an Alternate Source Contract which will not extend for a
period longer than the length of any stated Failure Period; provided, however, no Alternate Source Contract shall extend for a period longer than six (6) months unless consented to in writing
by the Suspending Party, or unless the Failure Period described in any Suspension Notice is greater than six (6) months (in which case an Alternate Source Contract may extend for the length of
the Failure Period described in the Suspension Notice). 

        11.5   If
any Failure Period continues for a period in excess of twelve (12) months, or if the Suspension Notice states that the Failure Period will
continue for greater than twelve (12) months, the Recipient Party may at its option terminate this Agreement, only with respect to the Licensed MP Products or services subject to such force
majeure, by thirty (30) days written notice. If not terminated, however, this Agreement shall remain in full force and effect until this Agreement is terminated by its terms. 

        12.    ASSIGNMENT.    

        12.1   Except
as otherwise expressly provided herein, this Agreement may not be assigned by either party hereto, whether by operation of law or otherwise,
without the prior written consent of the other party hereto, and any such attempted assignment shall be void and unenforceable; provided, however, that either party may assign its rights and
obligations hereunder without the consent of the other party to an Affiliate of such party, or to a successor in interest to substantially all of the stock, equity or assets of such party to which
this Agreement relates. 

        13.    NOTICES.    

        13.1   All
notices which are required or permitted to be given pursuant to the terms of this Agreement shall be in writing and shall be deemed effective:
(i) upon receipt if given in writing and delivered personally; or (ii) five (5) business days after it shall have been deposited in the United States mails, registered or
certified mail, postage prepaid; or (iii) one (1) day after it shall have been delivered to an overnight courier service, such as Federal Express, all charges prepaid, addressed as
follows: 

If
to MProbes, to: 

Molecular
Probes, Inc.

4849 Pitchford Avenue

Eugene. OR 97402

Phone: 541.465.8300

Fax: 541.465.8354

Attention: Legal Department;

and 

10

 

If
to Immunicon, to: 

Edward
L. Erickson

Chairman and Chief Executive Officer

Immunicon Corporation

3401 Mason Mill, Suite 100

Huntingdon Valley, PA 19006

Phone: 215.830.0777

Fax: 215.830.0751 

Any
of the addresses or addressees set forth in this Article may be changed from time to time by written notice from the party requesting the change. 

        14.    CONFIDENTIALITY OF INFORMATION.    

        14.1   The
parties may wish, from time to time, in connection with this Agreement, to disclose certain of their confidential information to each other. While
this Agreement is in effect and for five (5) years thereafter, a party receiving any such confidential information (the "Receiving Party") shall not itself use for any purpose other than for
which it was disclosed, and shall prevent the disclosure to third parties of, any and all of such confidential information, provided that the Receiving Party's obligation hereunder shall not apply to
information that: 

        a)    is
already in the Receiving Party's possession at the time of disclosure thereof, as evidenced by its written records; 

        b)    is
or subsequently becomes part of the public domain through no fault or action of the Receiving Party; 

        c)     is
subsequently received by the Receiving Party from a third party having no obligation of confidentiality to the party disclosing the confidential information; or 

        d)    is
disclosed to third parties as required by law or governmental regulation. 

        14.2   Paragraph 14.1
notwithstanding, information disclosed by one party to another shall still be deemed confidential information of the party
disclosing such information subject to the protection of this Article 14 if such disclosed information is: 

        a)    a
specific embodiment that is only generally described by information in the public domain or the Receiving Party's possession; or 

        b)    a
combination that can be pieced together and reconstructed from multiple sources, none of which shows the whole combination of materials, its principle of operation, and
method of use. 

        15.    CONTRACT INTERPRETATION.    

        15.2    Governing Law.    This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Pennsylvania, without giving regard to its choice of law or conflict of laws provisions. 

        15.3    Publicity.    Neither party shall issue any press release or other publicity materials, or make any
presentation with respect to the existence of this Agreement or the terms and conditions hereof without the prior written consent of the other party, which consent shall not be unreasonably withheld.
This restriction shall not apply to disclosures required by law or regulation, including as may be required in connection with any filings made with the US Securities and Exchange Commission or by the
disclosure policies of a major Stock Exchange. 

11

 

        15.4    Modification and Amendment.    No supplement, modification or amendment of this Agreement, including the
Appendices thereof, shall be binding unless in writing and executed by MProbes and Immunicon. 

        15.5    Severability.    To the extent that any provision of this Agreement is found by a court of competent
jurisdiction to violate any applicable law or regulation in any jurisdiction, or does so in the opinion of counsel mutually acceptable to both parties, such provision shall be deemed modified only in
that jurisdiction and only to the extent necessary to comply with such law or regulation. In such circumstances, the parties agree to negotiate in good faith amendments to this Agreement designed to
restore to the parties the economic benefits they held under this Agreement prior to the modification. 

        15.6    Counterparts and Headings.    This Agreement may be executed in one or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. All headings and captions are inserted for convenience of reference only and shall not affect the meaning
or interpretation of any provision hereof. 

        15.7    Relationship of the Parties.    The status of Immunicon and MProbes hereunder is solely that of independent
contractors. This Agreement shall not create an agency, partnership, joint venture, or employer/employee relationship between the parties, and nothing hereunder shall be deemed to authorize either
party to act for, represent or bind the other except as expressly provided in this Agreement. 

        15.8    Waiver.    No waiver of any right under this Agreement shall be deemed effective unless contained in writing
and signed by the party charged with such waiver, and no waiver of any right shall be deemed to be a waiver of any future right or any other right arising under this Agreement. All rights, remedies,
undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement. 

        15.9    Patents and Trademarks.    No right or license is granted by either party hereunder, except as expressly
stated herein, to use or practice any patent rights of the other party, or to use the name, trademarks or tradenames of the other party. Nothing in this Agreement shall be construed as conferring any
right on either party to use or exploit any trade secret or other proprietary right of the other party, except as expressly set forth herein or as may be otherwise separately agreed in writing by the
parties. 

        15.10    Dispute Resolution.    In the event of any dispute between the parties concerning this Agreement, the parties
shall first attempt a resolution thereof by referring the dispute to senior management representatives of each party who shall discuss the matter between them and attempt to reach a reasonable
compromise or other disposition of the dispute. In the event such a compromise or disposition cannot be achieved, the dispute shall be referred to Endispute or a similar dispute resolution
organization for a decision, in accordance with the rules of dispute resolution proceedings of such organization, resolving the dispute, which decision shall be binding upon the parties. 

        15.11    Entire Agreement.    This Agreement constitutes the entire agreement between the parties hereto relating to
the subject matter hereof and supersedes all prior or contemporaneous negotiations, representations, agreements and understandings of the parties relating thereto, whether written or oral. Any
Appendices referred to in this Agreement are incorporated by reference and made a part of this Agreement. The terms of any purchase order, equivalent document or acknowledgement prepared in connection
with this Agreement shall be binding on the parties only to the extent not inconsistent herewith. 

12

 

        IN
WITNESS WHEREOF, the parties hereto have set their hands through their authorized representatives, whereby they evidence their intention to be legally bound. 

	Molecular Probes, Inc.	 	Immunicon Corporation
	

By:	

/s/ RICHARD P. HAUGLAND
	
 	

By:	

/s/ EDWARD L. ERICKSON

	Name:	Richard P. Haugland, Ph.D.
	 	Name:	Edward L. Erickson

	Title:	President
	 	Title:	Chairman, President and CEO

	Date:	11/15/00
	 	Date:	11/17/00

13

APPENDIX A: IC HARDWARE AND MAGNETIC SEPARATION MATERIALS, Corresponding IC Trademark, Relevant Specifications, and Delivery Schedule  

	Item
 
	 	Corresponding IC Trademark
	 	Relevant Specifications
	 	Delivery Schedule

	MAGNETIC SEPARATION MATERIALS: Immunicon's proprietary ferrofluids [**]	 	[none at this time]	 	[to be agreed between the parties in writing]	 	[to be agreed between the parties in writing]
	

IC HARDWARE: IC Magnets	
 	

[none at this time]	
 	

[to be agreed between the parties in writing]	
 	

[to be agreed between the parties in writing]

Appendix
A agreed to and accepted by: 

	Molecular Probes, Inc.	 	Immunicon Corporation
	

By:	

/s/ RICHARD P. HAUGLAND
	
 	

By:	

/s/ EDWARD L. ERICKSON

	Name:	Richard P. Haugland, Ph.D.
	 	Name:	Edward L. Erickson

	Title:	President
	 	Title:	Chairman, President and CEO

	Date:	11/15/00
	 	Date:	    

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

APPENDIX B: Pricing Schedule, Unit Size, Minimum Order  

	Item
 
	 	Unit Size
	 	Minimum Order
	 	Pricing Schedule

	MAGNETIC SEPARATION MATERIALS:

  

Immunicon's proprietary ferrofluids [**]	 	[**]	 	at least [**] per purchase order, which purchase MProbes might receive from Immunicon in multiple shipments, at MProbes' option	 	MProbes' base purchase price for the [**] shall be [**], but MProbes shall [**]. The base price shall remain the same during the first twenty-four months after the Effective Date of the Agreement, but may be adjusted once
in every twelve-month period thereafter, at Immunicon's option, in accordance with the corresponding change in the producer price index for intermediate materials/other miscellaneous metal products.
	

IC HARDWARE:

 

IC Magnets	
 	

[**]	
 	

at least [**] per purchase order, which purchase MProbes might receive from Immunicon in multiple shipments, at MProbes' option	
 	

MProbes' purchase price for the current version of IC Magnets would be no greater than [**] for Immunicon's purchase and assembly of IC Magnets, which Immunicon's purchase and assembly of IC Magnets, which purchase price may be adjusted every quarter,
 as agreed between the parties, to maximize total sales of both IC Magnets and products containing [**].
	
	 	 	 	 	 	 

Appendix
B agreed to and accepted by: 

	Molecular Probes, Inc.	 	Immunicon Corporation
	

By:	

/s/ RICHARD P. HAUGLAND
	
 	

By:	

/s/ EDWARD L. ERICKSON

	Name:	Richard P. Haugland, Ph.D.
	 	Name:	Edward L. Erickson

	Title:	President
	 	Title:	Chairman, President and CEO

	Date:	11/15/00
	 	Date:	    

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

APPENDIX C: LICENSED MP PRODUCTS that MProbes can manufacture and sell, and Corresponding Royalty Payments, Fees and Other Payments  

	Authorized Products
 
	 	Royalty Payments
	 	Fees and Other Payments

	LICENSED MP

PRODUCTS:

  

conjugates [**], other than streptavidin conjugates of [**], but including CaptAvidin(1) biotin-binding protein conjugates of [**]; such conjugates of [**] may be sold by MProbes as catalog items or as custom products for the Licensed Use	 	 

 

 

royalty of [**] on Net Sales of conjugates of [**] that are sold as standalone reagents;

for conjugates of [**] that are sold in kits, a royalty on such Net Sales that is the greater of

a) [**]% of such Net Sales of kits, or

b) [**]% of the price of the equivalent amount (mg) of conjugate if sold separately or, if no such conjugate is sold separately, of the equivalent amount of a comparable conjugate that is sold separately	 	  

  

  

[**] MProbes purchases of [**] and IC Magnets during the term of the Agreement

	(1)
	CaptAvidin
is MProbes' trademark for biotin-binding protein technology covered by US Patent No. 5,973,124, filed June 13, 1996, issued October 26, 1999 (and any related patents)
licensed to MProbes by Baxter Healthcare Corporation. 

Appendix
C agreed to and accepted by: 

	Molecular Probes, Inc.	 	Immunicon Corporation
	

By:	

/s/ RICHARD P. HAUGLAND
	
 	

By:	

/s/ EDWARD L. ERICKSON

	Name:	Richard P. Haugland, Ph.D.
	 	Name:	Edward L. Erickson

	Title:	President
	 	Title:	Chairman, President and CEO

	Date:	11/15/00
	 	Date:	    

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

APPENDIX D: Patent Coverage of IC TECHNOLOGY  

	Item
 
	 	Patent Coverage
 

	MAGNETIC SEPARATION MATERIALS:

  

Immunicon's proprietary ferrofluids [**]	 	[**]

  

[**]

  

[**]

  

[**]

  

[**]

  

[**]

 

[**]
	

IC HARDWARE: IC Magnets	
 	

US 5,186,827 Apparatus for magnetic separation featuring external magnetic means

  

US 5,200,084 Apparatus and methods for magnetic separation

Appendix
D agreed to and accepted by: 

	Molecular Probes, Inc.	 	Immunicon Corporation
	

By:	

/s/ RICHARD P. HAUGLAND
	
 	

By:	

/s/ EDWARD L. ERICKSON

	Name:	Richard P. Haugland, Ph.D.
	 	Name:	Edward L. Erickson

	Title:	President
	 	Title:	Chairman, President and CEO

	Date:	11/15/00
	 	Date:	11/17/00

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

APPENDIX A: IC HARDWARE AND MAGNETIC SEPARATION MATERIALS, Corresponding IC Trademark, Relevant Specifications, and Delivery Schedule [Amended on June 26,
2001]  

	Item
 
	 	Corresponding

IC Trademark
	 	Relevant Specifications
	 	Delivery Schedule

	MAGNETIC SEPARATION MATERIALS:	 	[none at this time]	 	 	 	 	 	 
	

Immunicon's proprietary ferrofluids [**]	
 	

 	
 	
Test
 [**]	
 	
Specification
 [**]	
 	

Within 6 weeks of receipt of an order.
	 	 	 	 	[**]	 	[**]	 	 
	 	 	 	 	[**]	 	[**]	 	 
	

Streptavidin Ferrofluid ("IC Streptavidin Ferrofluid")	
 	

 	
 	
Test
 [**]	
 	
Specification
 [**]	
 	

Within 6 weeks of receipt of an order.
	 	 	 	 	[**]	 	[**]	 	 
	 	 	 	 	[**]	 	[**]	 	 
	

IC HARDWARE:	
 	

[none at this time]	
 	

 	
 	

 	
 	

 
	

Individual IC Magnets	
 	

 	
 	

Visual inspection, underlying product warranted by Immunicon per para. 10.3.	
 	

Within 8 weeks of receipt of an order.
	

—Magnet/Yoke assembly for microscope ("IC Magnet/Yoke Assembly"). Magnet yokes will be provided 1 per box in plastic box with foam insert and with clear lid, with no label. MProbes will label.	
 	

 	
 	
Test
 Inner dimension of chamber cavity:	
 	
Specification
 Width: 1.216-1.220 inches

Height: .368-.372 inches	
 	

Within 8 weeks of receipt of an order.
	 	 	 	 	Magnetic qualities:	 	Magnets must have opposing polarities	 	 
	 	 	 	 	Field strength:	 	[**]	 	 
	 	 	 	 	Serial Number:	 	Present, etched on back of yoke.	 	 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

	

—Sample Chambers and Plugs ("IC Sample Chambers and Plugs"). MProbes supplies labels for individual chambers. Immunicon puts MProbes label on individual chamber and chambers are shrink-wrapped in trays of 10. Plugs are unlabeled and packaged 10
per sealable plastic bag. MProbes will label the outer container with its own label.	
 	

 	
 	
Test
 Pressure Test:	
 	
Specification
 [**]	
 	

Within 6 weeks of receipt of an order.
	 	 	 	 	Visual Appearance:	 	[**]	 	 
	 	 	 	 	Adhesive Bond:	 	[**]	 	 
	 	 	 	 	Fit:	 	[**]	 	 
	 	 	 	 	Serial Number:	 	[**]	 	 

Appendix
A, as amended, agreed to and accepted by: 

	Molecular Probes, Inc.	 	Immunicon Corporation
	

By:	

/s/ RICHARD P. HAUGLAND
	
 	

By:	

/s/ EDWARD L. ERICKSON

	Name:	Richard P. Haugland, Ph.D.
	 	Name:	Edward L. Erickson

	Title:	President
	 	Title:	Chairman, President and CEO

	Date:	6/26/01
	 	Date:	6/27/01

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

APPENDIX B: Pricing Schedule, Unit Size, Minimum Order [Amended on June 26, 2001]  

	Item
 
	 	Unit Size
	 	Minimum Order
	 	Pricing Schedule

	MAGNETIC SEPARATION MATERIALS:	 	 	 	 	 	 
	

Immunicon's proprietary ferrofluids [**]	
 	

[**]	
 	

at least [**] per purchase order, which purchase MProbes might receive from Immunicon in multiple shipments, at MProbes' option	
 	

MProbes' base purchase price for the [**] be [**], but MProbes shall [**]. The base price shall remain the same during the first twenty-four months after the Effective Date of the Agreement, but may be adjusted once in every twelve-month period
thereafter, at Immunicon's option, in accordance with the corresponding change in the producer price index for intermediate materials/other miscellaneous metal products.
	

Streptavidin Ferrofluid ("IC Streptavidin Ferrofluid")	
 	

[**]	
 	

At least [**] per order	
 	

MProbes' base purchase price for the IC Streptavidin Ferrofluid shall be $[**], but if volumes greater than or equal to [**] per year of the Agreement are purchased, MProbes will be [**], against future purchases of IC Streptavidin Ferrofluid. The
base price shall remain the same during the first twenty-four months after the Effective Date of the Agreement, but may be adjusted once in every twelve-month period thereafter, at Immunicon's option, in accordance with the corresponding change in
the producer price index for intermediate materials/other miscellaneous metal products.

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

	

IC HARDWARE:	
 	

 	
 	

 	
 	

 
	

Individual IC Magnets	
 	

[**]	
 	

at least [**] magnets per purchase order, which purchase MProbes might receive from Immunicon in multiple shipments, at MProbes' option	
 	

MProbes' purchase price for the current version of IC Magnets would be no greater than [**] for Immunicon's purchase and assembly of IC Magnets, which purchase price may be adjusted every quarter, as agreed between the parties, to maximize total
sales of both IC Magnets and products containing IC BSA Ferrofluids.
	

—Magnet/Yoke assembly for microscope ("IC Magnet/Yoke Assembly")	
 	

[**]	
 	

[**]	
 	

[**]
	

—Sample Chambers and Plugs ("IC Sample Chambers and Plugs")	
 	

Bulk packaged—[**] labels supplied by MProbes applied to each Unit.	
 	

[**]	
 	

[**]

Appendix
B, as amended, agreed to and accepted by: 

	Molecular Probes, Inc.	 	Immunicon Corporation
	

By:	

/s/ RICHARD P. HAUGLAND
	
 	

By:	

/s/ EDWARD L. ERICKSON

	Name:	Richard P. Haugland, Ph.D.
	 	Name:	Edward L. Erickson

	Title:	President
	 	Title:	Chairman, President and CEO

	Date:	6/26/01
	 	Date:	6/27/01

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

APPENDIX C: LICENSED MP PRODUCTS that MProbes can manufacture and sell, and Corresponding Royalty Payments, Fees and Other Payments [Amended on June 26,
2001]  

	Authorized Products
 
	 	Royalty Payments
	 	Fees and Other Payments

	LICENSED MP

PRODUCTS:

  

conjugates of [**], which for royalty purposes hereunder shall include, without limitation, IC Strepavidin Ferrofluid and streptavidin conjugates of [**], but and including CaptAvidin(1) biotin-binding protein conjugates of [**]; such conjugates of
[**] may be sold by MProbes as catalog items or as custom products for the Licensed Use	 	  

  

  

royalty of [**] on Net Sales of conjugates of [**] that are sold as standalone reagents;

for conjugates of [**] that are sold in kits, a royalty on such Net Sales that is the greater of

a) [**]% of such Net Sales of kits, or

b) [**]% of the price of the equivalent amount (mg) of conjugate if sold separately or, if no such conjugate is sold separately, of the equivalent amount of a comparable conjugate that is sold separately	 	  

  

  

[**] MProbes' purchases of [**] and IC Magnets during the term of the Agreement

	(1)
	CaptAvidin
is MProbes' trademark for biotin-binding protein technology covered by US Patent No. 5,973,124, filed June 13, 1996, issued October 26, 1999 (and any related patents)
licensed to MProbes by Baxter Healthcare Corporation. 

Appendix
C, as amended, agreed to and accepted by: 

	Molecular Probes, Inc.	 	Immunicon Corporation
	

By:	

/s/ RICHARD P. HAUGLAND
	
 	

By:	

/s/ EDWARD L. ERICKSON

	Name:	Richard P. Haugland, Ph.D.
	 	Name:	Edward L. Erickson

	Title:	President
	 	Title:	Chairman, President and CEO

	Date:	6/26/01
	 	Date:	6/27/01

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

QuickLinks

NON-EXCLUSIVE LICENSE and SUPPLY AGREEMENT between IMMUNICON CORPORATION and MOLECULAR PROBES, INC.QuickLinks
 -- Click here to rapidly navigate through this document

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

 
 

Exhibit 10.33    
    

AGREEMENT  

        Pfizer Inc, a Delaware corporation with a business address of 235 East 42nd Street, New York, NY 10017 and its
Affiliates ("Pfizer"), and Immunicon Corporation, a Delaware corporation with a business address of 3401 Masons Mill Road, Suite 100, Huntington Valley,
PA 19006, and its Affiliates ("Immunicon"), enter into this Agreement for services set forth in the exhibits ("Exhibits") attached to and made part of this Agreement, from time to time, on the
following terms and conditions: 

        1.    DEFINITIONS:    

        1.1   "Affiliates"
shall mean with respect to either party, any corporation, firm, partnership or other entity which directly or indirectly controls, is controlled by, or is
under common control with such party. 

        1.2   "Cell
Line" has the meaning set forth in any of the Exhibits. 

        1.3   "Results"
shall mean all information that results from Services (as defined herein). 

        1.4   "Sample"
has the meaning set forth in any of the Exhibits. 

        2.    SCOPE OF WORK:    The work to be performed by Immunicon under this Agreement ("Services") shall be as set forth
in the Exhibits attached to and made part of this Agreement, but in each case such Services shall be only to the extent as confirmed by Pfizer's Purchase Orders corresponding to such Exhibits
similarly attached to and made a part of this Agreement. Immunicon will use reasonable efforts to complete the Services in a professional and diligent manner, on the schedule and at the price stated
in the Exhibit and as defined in each Purchase Order. 

        3.    TERM:    The term of this Agreement is one (1) year from the date of its execution by Immunicon or until the
completion of the Services, whichever comes later. 

        4.    PAYMENT:    In consideration for Immunicon's performance of Services under this Agreement, Pfizer will pay
Immunicon in accordance with the payment amounts and schedule of each Exhibit corresponding to Services performed hereunder. Pfizer will do so against Immunicon's invoice referencing the Exhibit and
the purchase order for that Exhibit, and describing the Services performed. Payment will be due within forty five (45) days after Pfizer receives such invoice. 

        5.    INTELLECTUAL PROPERTY:    Each party will retain ownership of its Information and Intellectual Property
furnished to the other party in connection with this Agreement. Notwithstanding any other provision of this Agreement, Immunicon acknowledges that Pfizer will use the Results of the Services as it
sees fit in the development and commercialisation of Pharmaceutical products, and Pfizer acknowledges that Immunicon will use the Results of the Services which are generated solely by Immunicon as it
sees fit in the development and commercialisation of diagnostic and screening products. 

        6.    INFORMATION:    For purposes of this Agreement, the term "Information" means Results and any information that
Immunicon may receive from Pfizer pursuant to this Agreement, where such information received from Pfizer: (a) if Immunicon receives it in written form, is marked "Confidential" and;
(b) if Immunicon does not receive it in written form, is summarized by Pfizer in writing provided to Immunicon and declared by Pfizer in writing to be confidential within thirty
(30) days after disclosure. 

        7.    CONFIDENTIALITY:    Immunicon shall maintain the Information in confidence with the same degree of care it holds
its own confidential information. Immunicon shall not use the Information 

 

except
to perform the Services. Immunicon will disclose the Information only to its officers and employees directly concerned with the Exhibits and Purchase Orders, but will neither disclose the
Information to any third party nor use the Information for any other purpose except as otherwise expressly permitted by this Agreement. 

        8.    EXCEPTIONS TO CONFIDENTIALITY:    Immunicon's obligation of nondisclosure and the limitations upon the right to
use the Information shall not apply to the extent that Immunicon can demonstrate that the Information: (a) was in the possession of Immunicon prior to the time of disclosure; or (b) is
or becomes public knowledge through no fault or omission of Immunicon; or (c) is obtained by Immunicon from a third party under no obligation of confidentiality to Pfizer; or (d) is
necessary to be disclosed in connection with patent filings, or as may be required to be disclosed in submissions to governmental regulatory authorities, or is required by law or regulations of a
governmental entity to be disclosed. All Information will be returned or, in the case of the Exhibit, delivered to Pfizer upon termination of this Agreement for any reason, except for one copy, which
Immunicon may use for the sole purpose of determining its continuing confidentiality obligation to Pfizer under this Agreement. 

        9.    SURVIVAL OF CONFIDENTIALITY OBLIGATION:    All obligations of confidentiality with respect to Information of
Immunicon under paragraph 8 of this Agreement shall survive the termination of this Agreement for a period of five (5) years. 

        10.    INDEMNIFICATION:    Pfizer shall defend, indemnify and hold harmless Immunicon, its employees, directors and
officers, from and against any and all liability which it may incur, by reason of Pfizer's use of the Results. Under no circumstances will Immunicon be liable for any special, indirect or punitive
damages. 

        11.    NOTICES:    Any notices permitted or required pursuant to this Agreement shall be deemed effective if made in
writing and sent, postage prepaid, return receipt requested, or by overnight delivery as follows: 

	If to Pfizer:	 	Pfizer Global R&D Headquarters

50 Pequot Avenue

New London, CT 06320

Attn.: Executive Vice President, PGRD

with copy to: Assistant General Counsel
	

 	
 	

Invoices should be sent to the attention of

Dana D. Hendricks, Ph.D.

at the following address:
	

 	
 	

50 Pequot Avenue

MS6025-C4140

New London, CT 06320
	
If to Immunicon:	
 	

Immunicon Corporation

3401 Masons Mill, Suite 100

Huntingdon Valley, PA 19006

Attention: Chief Financial Officer

with copy to: Chief Counsel

        12.    ENTIRE AGREEMENT:    This Agreement, Exhibits, Purchase Orders, and invoices issued by either party pursuant to
it, set forth the entire agreement between Pfizer and Immunicon as to its subject matter. None of the terms of this Agreement shall be amended except in a writing signed by both parties. In the event
of any conflict or inconsistency between the terms and conditions of any 

2

 

Exhibit,
Purchase Order or invoice and the terms and conditions of the body of this Agreement, the latter shall govern and control. 

        13.    TERMINATION:    Pfizer may terminate this Agreement with or without cause by giving five (5) business
days notice to Immunicon in writing. If Pfizer terminates this Agreement, Pfizer's only obligation shall be to pay Immunicon for the Services performed up to the date of termination, at the rate
provided under this Agreement, plus payment for any non-cancellable obligations in connection with Services incurred by Immunicon or which Immunicon is obligated to pay at the request or
approval of Pfizer. 

        14.    BREACH:    If either party materially breaches this Agreement, the other may terminate it if the breaching
party does not cure the breach within sixty (60) days of receipt of written notice of same.
Termination shall be without prejudice to any rights which may have been accrued to either party before termination. 

        15.    FORCE MAJEURE:    Neither Pfizer nor Immunicon shall be liable for failure of or delay in performing
obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes reasonably beyond the control of
Pfizer or Immunicon. 

        16.    AUTHORITY AND COMPLIANCE:    Each party represents that it has the right and authority to enter into and
perform its obligations under this Agreement. Immunicon will perform all of its obligations under this Agreement in accordance with all applicable governmental laws, rules and regulations. 

        17.    CHOICE OF LAW:    This Agreement shall be construed in accordance with the laws of the State of New York. 

        IN WITNESS WHEREOF the parties have caused this Agreement to be executed and delivered by their duly authorized representatives. 

	Immunicon Corporation	 	Pfizer Inc
	

By:	

/s/  EDWARD L. ERICKSON      
	
 	

By:	

/s/  ALAN R. PROCTOR      

	Name:	Edward L. Erickson
	 	Name:	Dr. Alan R. Proctor

	Title:	Chairman, President & CEO
	 	Title:	Vice President, Strategic Alliances

	Date:	2/10/03
	 	Date:	1/24/03

3

 
 
 

Exhibit A    
    

DEVELOPMENT
OF METHODOLOGIES FOR THE ACCESS AND EVALUATION OF RARE CIRCULATING CELLULAR EVENTS IN HUMAN BLOOD. 

Rationale 

        The
implementation of pharmacodynamic markers as decision points in the development of oncology products requires access to specimens collected during clinical trials as well as access
to specimens collected at pilot or methodology studies for biomarker development. Two major obstacles are presented to the implementation of this strategy: clinical feasibility and technical
feasibility. The major obstacle to clinical feasibility is sample access, whereas lack of sensitivity is the major technical limitation. The use of highly sensitive methods of assessment of tumor and
other rare cells (e.g. tumor antigen specific CTLs) may be able to overcome some of these limitations. 

        Importantly, since the collection of blood samples, in a number that does not affect patient safety, is not considered a burden to the implementation of oncology
trials, it may be anticipated that, in addition to the specific project samples that would be directly procured and analyzed during this agreement, a successful collaboration with Immunicon may
indirectly have an overall impact on the feasibility of a biomarker strategy implementation in a multitude of oncology programs.

Background 

        Immunicon
is the developer of the CellTracks system. In the CellTracks system, cell analysis is undertaken in a single step of immunomagnetic selection and alignment. Specific cell
targets are recognized by magnetically and fluorescent-labeled reagent antibodies coupled to nanoparticle probes. Magnetically and fluorescent- labeled cells are aligned along ferromagnetic lines of
nickel (Ni) present on the upper surface of a chamber and are then scanned by a 635-nm laser focused by a compact disk (CD) objective. Importantly, cells maintain their position by
magnetic forces, which create the possibility to revisit cells of interest. 

        In contrast to other analytical platforms (e.g., flow cytometry, hematology analyzers, and laser scanning cytometry), only cells identified by the presence of a
defined antigen are presented to the optical detection system. That is, if one is for example interested in analyzing the number and signal intensity of circulating tumor cells
in blood expressing an specific marker, antibodies against that marker labeled with fluorescent dyes and magnetic nanoparticles dies are employed to mark the cells of interest. Those particular cells
that express the antigen of interest will move through the blood under the influence of the system's magnetic gradient and present themselves to the optical detection system. Consequently, the
analysis can be performed in the presence of all blood constituents (including treatment drugs) and no extensive sample preparation is needed. Thus, this platform is significantly less complex and
more sensitive and faster than current flow analysis equipment and may provide additional functionality through its ability to subject the cells to repeated and/or varied analyses while they remain in
a natural environment (i.e., whole blood). 

Proposal 

        We
seek to establish a research agreement with Immunicon to development and validation of methods for the analysis of rare circulating cells in blood. Potential rare circulating cells
are tumor cells, endothelial cells and precursors, tumor antigen specific immune cells, and antigen presenting cells, among others. 

4

 

        In
a first step of this agreement, [**] pilot projects will be developed before [**]. Target projects will be proposed by Pfizer Inc and
their feasibility discussed with Immunicon. Final pilot projects will be decided by agreement of Pfizer and Immunicon. Potential pilot projects include: 

	•
	[**]

	•
	[**]

        Pfizer
Inc will select clinical sites and investigators for the development and validation of these methodologies, as well as provide clinical funding and monitoring for the projects as
part of the overall proposal. 

        Materials
and equipment will be provided by Immunicon. 

Cost (2003-2004) 

        Immunicon
cost: $ 200 K total to be distributed as follows: 

        $50K
upfront payment upon signing of contract agreement and 

        $75K
on July 1st 2003 upon receipt and approval by Pfizer of feasibility and initial validation reports for the projects. 

        $75K
on March 1st 2004 upon receipt and approval by Pfizer of final reports for the projects. Should for any reason Pfizer would not be able to not supply
the [**] samples for analysis, then Immunicon will be notified and this last payment of $75K will not be made to Immunicon.

Proposal Objectives AND Timelines  

First quarter 2003  

	•
	[**]

Second quarter 2003  

	•
	[**] 

First quarter 2004  

	•
	[**]

	•
	[**]

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

5

 

	•
	[**]

Laboratory Objectives 

        For
a pharmacodynamic assay to be employed as a clinical endpoint, one must be certain that the test is able to provide accurate, reproducible and discriminating information. The
performance of a test is usually defined by its performance specifications of bias, imprecision, reportable range, interference, recovery and detection limit. 

        Bias, systematic error or inaccuracy, is primarily an analytic specification in which reported results differ systematically from the
actual value. Test bias is determined by a comparison of methods experiment. In this experiment, bias is calculated on the basis of the differences
between the results of the test under evaluation and a comparative method or a "gold standard". In the absence of a gold standard, spiking of samples could be employed or other methods of analysis. 

        A
minimum of 40 different patient specimens should be tested by the two methods. Importantly, the term "comparative" does not necessarily imply correctness or gold standard. As with many
laboratory methods, available tests may fall within the category of state-of-the-art technology. If the differences between methods are small, then we may conclude
that both methods have the same relative accuracy. If the differences are large and unacceptable, then it will be necessary to identify which method is inaccurate. Recovery and interference
experiments can be employed to provide discriminating information. 

        Test
imprecision, also known as random error or lack of reproducibility, may be due to
preanalytical and analytical factors. Determining the amount of imprecision by replication experiments should be one of the first steps in a method
validation study. Several factors must be considered in the design of these experiments, including, experimental time period, sample matrix, materials and number of samples to be analyzed.
Within-run or within-day replication experiments may be sufficient to offer an estimate of short-term imprecision, but total (between-day) imprecision
is preferred. However, the between-day component of test imprecision may not be investigated unless replicates are assayed on different days, in which case the stability of the sample must
be demonstrated for the time period between them. 

        The
preanalytical factors may be multiple. In the baseline state, test results may fluctuate in an individual due to random or predictable variation; this is termed intra-individual
variation. The degree of variation may be increased under certain conditions, such as food intake, time of the day, exercise, acute illness, or other forms of stress. In addition, samples from an
individual could be taken at different times of the day, if daily rhythm were suspected, or at different days of the month, if monthly rhythms were suspected. It is commonly accepted that a minimum of
20 samples should be measured in the time period of interest. Aliquots of fresh patient samples may be used for short-term testing, (within-run) replication studies, if this is
possible. 

        Materials
present in a sample other that the analyte constitute its matrix. In evaluating method performance, it is important to use test
samples that have a matrix as close as possible to the specimen of interest. 

        Reportable range assesses the useful analytical range of a laboratory method, that is, the lowest and highest reliable test results that
set the margins of a measurable response. Samples in the high and low analytical range may be employed for these purposes. Dilutions of a sample may be employed if this is feasible. In general, a
minimum of at least 4- and preferably 5-different levels or concentrations are recommended. CLIA (Clinical Laboratory Improvemend Amendments, 1988) does not strictly require
that a method provide a linear response, but laboratories commonly use a "linearity" type of experiment to check the reportable range for a test. 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

6

 

        Bias, imprecision and reportable range complete validation requirements in most circumstances. However, in the case of tumor markers and immunoassay testing,
interference, recovery and detection limit may be subsequently assessed for further method validation.

        Detection limit experiments are intended to estimate the lowest concentration of analyte that can be detected. In these experiments, two
different kinds of samples are prepared. Usually, one sample is a "blank" that has a zero concentration of the analyte of interest. The second is a "spiked" sample that has a low concentration of the
analyte of interest. Different estimates of detection limit may be calculated from the data on blank and spiked samples. Ideally the blank solution should have the same matrix as the spiked sample.
Detection limit (or analytical sensitivity) must be verified only for high complexity methods, modified moderate complexity methods, and moderate complexity methods that have not been cleared by FDA
as meeting the CLIA requirements for quality control. 

        Interference
and recovery experiment may be run to investigate any source of systematic error. Interference errors are independent of the concentration of the analyte being tested.  Interference experiments should
test, among others, the effect of therapeutic agents on the analytical reagents employed. Finally,  recovery may be run to estimate the proportional systematic error. This is a type of error whose
magnitude increases as the concentration of analyte
increases and it is often caused by a substance in the sample matrix that reacts with the sought-for analyte and therefore competes with an analytical reagent. 

Subject Population 

Inclusion Criteria  

	•
	Disease
related

	1.
	[**]

	2.
	[**]

	3.
	[**]

	•
	Prior/Concurrent
Therapy

	1.
	[**]

	2.
	[**]

	3.
	[**]

	4.
	[**]

	5.
	[**]

	6.
	[**]

	•
	Patient
related

	1.
	[**]

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

7

 

	2.
	[**]

	3.
	[**]

	4.
	[**]

	5.
	[**]

	6.
	[**]

	7.
	[**]

	8.
	[**]

	9.
	Written
and voluntary consent. 

Exclusion Criteria  

	1.
	[**]

	2.
	[**]

	3.
	[**]

	4.
	[**]

	5.
	[**]

	6.
	[**]

	7.
	[**]

	8.
	[**]

	9.
	[**]

	10.
	[**] 

Specimen Collection and Handling  

	1.
	SPECIMEN
COLLECTION: 

        The
blood will be drawn by a physician, registered nurse, or a licensed phlebotomist at the clinical site. A maximum of "X"mL of peripheral blood will be drawn from each patient. The
blood will be collected into properly labeled 10mL CellSaveTM evacuated blood collection tubes (minimum of [**] of blood per tube). 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

8

 
	2.
	SHIPPING
AND HANDLING OF SPECIMENS: 

        The
CellSaveTM tubes must be maintained at ambient (10-30° C) temperature, avoiding extremes of heat and cold, at all times. The tubes must be
shipped overnight to Immunicon on the same date as the draw. 

        Laboratory
Contact Information: 

C/o
[**]

Immunicon—Clinical Services

3401 Masons Mill Road, Suite 100

Huntingdon Valley, PA 19006-3574

Phone:215-8300751 ext. 224 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

9

QuickLinks

Exhibit 10.33

Exhibit A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]